Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease

INTRODUCTION: We evaluated the selective M1 muscarinic positive allosteric modulator, MK-7622, as adjunctive cognitive enhancing therapy in individuals with Alzheimer's disease. METHODS: A randomized, double-blind, proof-of-concept trial was performed. Participants with mild-to-moderate Alzheim...

Descripción completa

Detalles Bibliográficos
Autores principales: Voss, Tiffini, Li, Jerry, Cummings, Jeffrey, Farlow, Martin, Assaid, Christopher, Froman, Samar, Leibensperger, Heather, Snow-Adami, Linda, McMahon, Kerry Budd, Egan, Michael, Michelson, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021552/
https://www.ncbi.nlm.nih.gov/pubmed/29955661
http://dx.doi.org/10.1016/j.trci.2018.03.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021552/
https://www.ncbi.nlm.nih.gov/pubmed/29955661
http://dx.doi.org/10.1016/j.trci.2018.03.004

Ejemplares similares